Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) traded at $2.93 at last check on Friday, Oct 09, making a downturn move of -1.35% on its previous day’s price.

Looking at the stock we see that its previous close was $2.97 and the beta (5Y monthly) reads 0.8 with the day’s price range being $2.8700 – 3.0100. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, SONN has a high of $54.6 and a low of $2.23. The company’s stock has gained about 15.35% over that past 30 days.

On the other hand, looking at the outlook for the SONN stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 1 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Sonnet BioTherapeutics Holdings, Inc. (SONN) stock as a Hold, while 1 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the SONN stock currently stands at 0, and the current price level is 12.52% off its SMA20 and 5.17% from its 50-day simple moving average. The RSI (14) is pointing at 62.16 while the volatility over the past week is 6.7% and drops to 6.57% over the past one month. The beta value is 0.8, while the average true range (ATR) is currently pointing at 0.17. The average price target for the stock over the next 12 months is $8, with the estimates having a low of $8 and a high of $8. These price ends are 173.04% and +173.04% off the current price level respectively, although investors could be excited at the prospect of a +173.04% if the SONN share price touches on the median price of $8.

Let’s briefly compare Sonnet (SONN) stock to its peers. We find that today’s price change of -1.35% and -86.39% over the past 12 months for SONN competes that of Amgen Inc (AMGN), which has seen its stock price fall -1.41% in the latest trading session and is +19.14% over the last one year. Another of its peers Bristol-Myers Squibb Company (BMY) has climbed 0.32% today, and is +21.74% up over the past year, while Gilead Sciences Inc (GILD) is also down -1.35% yet its price remains in the red at -86.39% over the same period. Amgen has a P/E ratio of 19.34 compared to Sonnet’s 0 and Bristol-Myers 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.88% and 0.57%, respectively, in early deals.

Coming back to Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), we note that the average 3-month trading volume was 4.5 Million, while that of the preceding 10-day period stands at 735.26 Million. Current shares outstanding are 13.64 Million.

According to data from Thomson Reuters, insiders hold 0.77% of the company’s shares while institutions hold 0.52%. The data shows that short shares as of September 14, 2020, stood at 1.42 Million at a short ratio of 0.25. This represents a 10.43% Short interest in Shares outstanding on September 14, 2020. Shares short dropped in September from the previous month at 827.91 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -80.9% down in year-to-date price movement.